# EDGAR Filing Document

**Accession Number:** 0001584693
**File Stem:** 0001493152-23-008541
**Filing Date:** 2023-3
**Character Count:** 114471
**Document Hash:** 76e40d867e355a19cadd617154783c6d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-008541.hdr.sgml**: 20230322

**ACCESSION NUMBER**: 0001493152-23-008541

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 71

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230322

**DATE AS OF CHANGE**: 20230322

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Healthcare Integrated Technologies Inc.
- **CENTRAL INDEX KEY:** 0001584693
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-AMUSEMENT & RECREATION SERVICES [7900]
- **IRS NUMBER:** 463052781
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36564
- **FILM NUMBER:** 23753118

**BUSINESS ADDRESS:**
- **STREET 1:** 1462 RUDDER LANE
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37919
- **BUSINESS PHONE:** 865-237-4448

**MAIL ADDRESS:**
- **STREET 1:** 1462 RUDDER LANE
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRASSHOPPER STAFFING, INC.
- **DATE OF NAME CHANGE:** 20160122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tomichi Creek Outfitters
- **DATE OF NAME CHANGE:** 20130819

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended January 31, 2023**

**OR**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ________ to ________**

**Commission file number: 001-36564**

![](form10q_001.jpg)

**Healthcare Integrated Technologies, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **Nevada** | **85-1173741** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (I.R.S. Employer<br> Identification No.) |

---

**1462 Rudder Lane**

**Knoxville, TN 37919**

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(865) 719-8160**

Securities registered pursuant to Section 12(b) of the Act: **None**

Securities registered pursuant to section 12(g) of the Act:

**Common Stock, $0.001 par value**

(Title of class)

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-Q or any amendment to this Form 10-Q. ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☐ Smaller reporting company ☐ <br> (Do not check if a smaller reporting company) Emerging growth company ☒

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 22, 2023, there were 45,282,384 shares of common stock of the Registrant outstanding.

Documents Incorporated by Reference: **None.**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [PART I - FINANCIAL INFORMATION](#ak_001) | F-1 |
| [Item 1. Financial Statements (Unaudited).](#ak_002) | F-1 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.](#ak_003) | 4 |
| [Item 3. Quantitative and Qualitative Disclosures about Market Risk.](#ak_004) | 11 |
| [Item 4. Controls and Procedures.](#ak_005) | 11 |
| [PART II - OTHER INFORMATION](#ak_006) | 12 |
| [Item 1. Legal Proceedings.](#ak_007) | 12 |
| [Item 1A. Risk Factors.](#ak_008) | 12 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#ak_009) | 12 |
| [Item 3. Defaults Upon Senior Securities.](#ak_010) | 12 |
| [Item 4. Mine Safety Disclosures.](#ak_011) | 12 |
| [Item 5. Other Information.](#ak_012) | 12 |
| [Item 6. Exhibits.](#ak_013) | 13 |
| [SIGNATURES](#ak_014) | 14 |

---

Unless the context clearly indicates otherwise, when used in this report "we," "us," "our," "Healthcare Integrated Technologies," "Company," or "our Company" refers to Healthcare Integrated Technologies, Inc. and, if applicable, our subsidiaries.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" within the meaning of the Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue," negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning: possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results; and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Form 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions, and beliefs about future events and are subject to risks, uncertainties, and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether resulting from new information, future events, a change in events, conditions, circumstances, or assumptions underlying such statements, or otherwise.

For discussion of factors that we believe could cause our actual results to differ materially from expected and historical results see "ITEM 1A – RISK FACTORS" included in our most recent Annual Report on Form 10-K for the year ended July 31, 2022 as filed with the United States Securities and Exchange Commission on September 23, 2022.

**PART I - FINANCIAL INFORMATION**

**Item 1. FINANCIAL STATEMENTS.**

**Index to Financial Statements**

---

| | |
|:---|:---|
|  | **Page** |
| **Quarterly Period Ended January 31, 2023** |  |
| [Interim Consolidated Balance Sheets](#ak_015) | F-2 |
| [Interim Consolidated Statements of Operations (Unaudited)](#ak_016) | F-3 |
| [Interim Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)](#ak_017) | F-4 |
| [Interim Consolidated Statements of Cash Flows (Unaudited)](#ak_018) | F-5 |
| [Notes to The Interim Consolidated Financial Statements (Unaudited)](#ak_019) | F-6 |

---

**HEALTHCARE INTEGRATED TECHNOLOGIES, INC.**

**INTERIM CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
|  | **(Unaudited)** |  |
| **ASSETS** |  |  |
| **CURRENT ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $16 | $1051 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 35339 | 36616 |
| Total current assets | 35355 | 37667 |
| **OTHER ASSETS:** |  |  |
| &nbsp;&nbsp;&nbsp;Intangibles, net | 781040 | 688353 |
| Total assets | $816395 | $726020 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| **CURRENT LIABILITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $237673 | $202973 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses, related party | 868481 | 641315 |
| &nbsp;&nbsp;&nbsp;Payroll related liabilities | 1594318 | 1452434 |
| &nbsp;&nbsp;&nbsp;Convertible notes | 275000 | 325000 |
| &nbsp;&nbsp;&nbsp;Notes payable, net | 650000 | 455605 |
| &nbsp;&nbsp;&nbsp;Derivative liability | 216082 | 76451 |
| Total current and total liabilities | 3841554 | 3153778 |
| **STOCKHOLDERS' DEFICIT:** |  |  |
| &nbsp;&nbsp;&nbsp;Common stock par value $0.001; 200,000,000 shares authorized; 42,830,061 and 42,304,673 shares issued and outstanding as of January 31, 2023 and July 31, 2022, respectively | 42830 | 42305 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 12102710 | 11839645 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (15170699) | (14309708) |
| Total stockholders' deficit | (3025159) | (2427758) |
| Total liabilities and stockholders' deficit | $816395 | $726020 |

---

*See accompanying notes to the interim consolidated financial statements.*

**HEALTHCARE INTEGRATED TECHNOLOGIES, INC.**

**INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Six Months Ended** | **For the Six Months Ended** |
|  | **January 31,** | **January 31,** | **January 31,** | **January 31,** |
|  | **2023** | **2022** | **2023** | **2022** |
| **OPERATING EXPENSES:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | $255161 | $314264 | $488642 | $655361 |
| Total operating expenses | 255161 | 314264 | 488642 | 655361 |
| **OPERATING LOSS** | (255161) | (314264) | (488642) | (655361) |
| **OTHER INCOME (EXPENSE):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (119832) | (106253) | (232718) | (212506) |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | 156894 | 26794 | (139631) | 59091 |
| Total other income (expense) | 37062 | (79459) | (372349) | (153415) |
| **NET LOSS** | $(218099) | $(393723) | $(860991) | $(808776) |
| **NET LOSS PER COMMON SHARE** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | $- | $(0.01) | $(0.02) | $(0.02) |
| **WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | 42444137 | 42085284 | 42473648 | 41172665 |

---

*See accompanying notes to the interim consolidated financial statements.*

**HEALTHCARE INTEGRATED TECHNOLOGIES, INC.**

**INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended January 31, 2023** | **Six Months Ended January 31, 2023** | **Six Months Ended January 31, 2023** | **Six Months Ended January 31, 2023** | **Six Months Ended January 31, 2023** | **Six Months Ended January 31, 2023** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** | **Common**<br>**Stock**<br>**Subscribed** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balances at July 31, 2022** | 42304673 | $42305 | $11839645 | $&nbsp;&nbsp;&nbsp;&nbsp; - | $(14309708) | $(2427758) |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (642892) | (642892) |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 90728 |  |  | 90728 |
| Activity for the three months ended October 31, 2022 | - | - | 90728 | - | (642892) | (552164) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (218099) | (218099) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares for services | 250000 | 250 | 13500 |  |  | 13750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares for the conversion of debt and related accrued interest | 120726 | 121 | 60242 |  |  | 60363 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 154662 | 154 | 98595 |  |  | 98749 |
| Activity for the three months ended January 31, 2023 | 525388 | 525 | 172337 | - | (218099) | (45237) |
| **Balances at January 31, 2023** | 42830061 | $42830 | $&nbsp;&nbsp;&nbsp;&nbsp;12102710 | $- | $(15170699) | $(3025159) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Six Months Ended January 31, 2022** | **Six Months Ended January 31, 2022** | **Six Months Ended January 31, 2022** | **Six Months Ended January 31, 2022** | **Six Months Ended January 31, 2022** | **Six Months Ended January 31, 2022** |
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** | **Common**<br>**Stock**<br>**Subscribed** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balances at July 31, 2021** | 40118007 | $40118 | $11039284 | $100000 | $(12948687) | $(1769285) |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (415053) | (415053) |
| &nbsp;&nbsp;&nbsp;Receipt of cash under stock subscription agreement |  |  |  | (25000) |  | (25000) |
| &nbsp;&nbsp;&nbsp;Issuance of shares and settlement of stock subscription | 1250000 | 1250 | 123750 | (75000) |  | 50000 |
| &nbsp;&nbsp;&nbsp;Issuance of shares under debt settlement and amendment agreement | 666666 | 667 | (667) |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 168394 |  |  | 168394 |
| Activity for the three months ended October 31, 2021 | 1916666 | 1917 | 291477 | (100000) | (415053) | (221659) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (393723) | (393723) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares for services | 170000 | 170 | 25330 |  |  | 25500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 168393 |  |  | 168393 |
| Activity for the three months ended January 31, 2022 | 170000 | 170 | 193723 | - | (393723) | (199830) |
| **Balances at January 31, 2022** | 42204673 | $42205 | $&nbsp;&nbsp;&nbsp;&nbsp;11524484 | $- | $(13757463) | $(2190774) |

---

*See accompanying notes to the interim consolidated financial statements.*

**HEALTHCARE INTEGRATED TECHNOLOGIES, INC.**

**INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Six months Ended January 31,** | **For the Six months Ended January 31,** |
|  | **2023** | **2022** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(860991) | $(808776) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 11865 | 5574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 163911 | 322970 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount | 194395 | 180000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | 139631 | (59091) |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1277 | 959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 40769 | 6245 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses, related party | 161700 | 161700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payroll related liabilities | 86552 | 86551 |
| NET CASH USED BY OPERATING ACTIVITIES | (60891) | (103868) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for intangible assets | (5610) | (25022) |
| NET CASH USED BY INVESTING ACTIVITIES | (5610) | (25022) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from related party loans | 65466 | 163400 |
| &nbsp;&nbsp;&nbsp;Payments of amounts owed to related parties |  | (70825) |
| &nbsp;&nbsp;&nbsp;Proceeds from common stock subscriptions | - | 25000 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 65466 | 117575 |
| Net change in cash and cash equivalents | (1035) | (11315) |
| **Cash and cash equivalents, beginning of period** | 1051 | 11443 |
| **Cash and cash equivalents, end of period** | $16 | $128 |
| **SUPPLEMENTAL CASH FLOW INFORMATION** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $20000 | $21600 |
| **SIGNIFICANT NON-CASH INVESTING AND FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures included in payroll related liabilities | $55333 | $91785 |
| &nbsp;&nbsp;&nbsp;Capital expenditures from stock-based compensation | $39316 | $39316 |
| &nbsp;&nbsp;&nbsp;Capital expenditures included in accounts payable and accrued expenses | $4294 |  |
| &nbsp;&nbsp;&nbsp;Issuance of common stock for payment of convertible debt | $50000 |  |
| &nbsp;&nbsp;&nbsp;Issuance of common stock for payment of items included in accounts payable and accrued expenses | $10363 |  |

---

*See accompanying notes to the interim consolidated financial statements.*

 

**HEALTHCARE INTEGRATED TECHNOLOGIES, INC.**

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**January 31, 2023**

**NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

Healthcare Integrated Technologies, Inc. and its subsidiaries (collectively the "Company," "we," "our" or "us") is a healthcare technology company based in Knoxville, Tennessee. We are creating a diversified spectrum of healthcare technology solutions to integrate and automate the continuing care, home care and professional healthcare spaces.

Our initial product, SafeSpace™ with AI Vision™, is an ambient fall detection solution designed for continuing care communities and at home use. SafeSpace includes hardware devices utilizing RGB, radar and other sensor technology coupled with our internally developed software to effectively monitor a person remotely. In continuing care communities, SafeSpace detects resident falls and generates alerts to a centralized, intelligent dashboard without the use of wearable devices or any action by the resident. In the home, SafeSpace detects falls and sends alerts directly to designated individuals.

In addition to SafeSpace, we are creating a home concierge healthcare service application to provide a virtual assisted living experience for seniors, recently released postoperative patients, and others. The concierge application will enable the consumer to obtain home healthcare services and health and safety monitoring equipment to improve quality of life. We are also working to develop a fully integrated solution for the professional healthcare community that integrates electronic health records, remote patient monitoring, telehealth, and other items where integration is beneficial.

***Basis of Presentation***

The accompanying interim consolidated financial statements include those of Healthcare Integrated Technologies, Inc. and its subsidiaries, after elimination of all intercompany accounts and transactions. We have prepared the accompanying interim consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the "SEC"). Accordingly, they do not contain all information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of the Company's management, the accompanying interim consolidated financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to fairly present the financial position of the Company as of January 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the six months ended January 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These interim consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended July 31, 2022 filed with the SEC on September 23, 2022.

***Reclassifications***

Certain prior period amounts may be reclassified to conform to current period presentation with no changes to previously reported net loss or stockholders' deficit.

***Risk and Uncertainties***

Factors that could affect our future operating results and cause actual results to vary materially from management's expectation include, but are not limited to: our ability to maintain and secure adequate capital to fund our operations and fully develop our product(s); our ability to source strong opportunities with sufficient risk adjusted returns; acceptance of the terms and conditions of our licenses and/or the acceptance of our royalties and fees; the nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations; changes in the projects in which we plan to invest which result from factors beyond our control, including, but not limited to, a change in circumstances, capacity and economic impacts; changes in laws, regulations, accounting, taxation, and other requirements affecting our operations and business. Negative developments in these or other risk factors could have a significant adverse effect on our financial position, results of operations and cash flows.

On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the "COVID-19 outbreak") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company's future financial condition, liquidity, and results of operations. Management is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2023.

***Use of Estimates***

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. We base our estimates on experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate our estimates and assumptions on a regular basis and actual results may differ from those estimates.

***Concentration of Credit Risk***

Financial instruments that potentially expose the Company to credit risk consist of demand deposits with a financial institution. The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institution to the extent account balances exceed the amount insured by the FDIC, which is $250,000.

***Cash and Cash Equivalents***

We consider all highly liquid short-term investments with a maturity of three months or less at the time of purchase to be cash equivalents. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. No loss has been experienced and management does not believe we are exposed to any significant credit risk.

***Accounts Receivable***

Accounts receivable are stated at their historical carrying amount net of write-offs and allowance for uncollectible accounts. We routinely assess the recoverability of all customer and other receivables to determine their collectability and record a reserve when, based on the judgement of management, it is probably that a receivable will not be collected and the amount of the reserve may be reasonably estimated. When collection is no longer pursued, we charge uncollectable accounts receivable against the reserve.

***Property and Equipment***

Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for major additions and improvements are capitalized while minor replacements and maintenance and repairs, which do not improve or extend the life of such assets, are charged to operations as incurred. Disposals are removed at cost less accumulated depreciation, and any resulting gain or loss is reflected in the interim consolidated statements of operations. Depreciation is calculated using the straight-line method which depreciates the assets over the estimated useful lives of the depreciable assets ranging from five to seven years.

 ****

***Impairment of Long-Lived Assets***

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment at least annually, or whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. The Company did not recognize any impairment losses for any periods presented.

***Intangible Assets***

Intangible assets consist of patents, our website and the costs of software developed for internal use. Certain payroll and stock-based compensation costs incurred are allocated to the intangible assets. We determine the amount of costs to be capitalized based on the time spent by employees or outside contractors on the projects. Intangible assets are amortized over their expected useful life on a straight-line basis. We evaluate the useful lives of these assets on an annual basis and test for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. If the estimate of an intangible asset's remaining life is changed, the remaining carrying value of the intangible asset is amortized prospectively over the revised remaining useful life. We did not recognize any impairment losses during any of the periods presented.

***Fair Value of Financial Instruments***

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2 Inputs – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

Level 3 Inputs – Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and borrowings. The fair value of current financial assets and current financial liabilities approximates their carrying value because of the short-term maturity of these financial instruments.

***Derivative Liability***

Options, warrants, convertible notes, or other contracts, if any, are evaluated to determine if those contracts, or embedded components of those contracts, qualify as derivatives to be separately accounted for in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 815, *"Derivatives and Hedging,"* (paragraph 815-10-05-4 and Section 815-40-25). The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. The change in fair value is recorded in the consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise, or cancellation and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated, and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

The Company adopted Section 815-40-15 of the FASB ASC *("Section 815-40-15")* to determine whether an instrument (or an embedded feature) is indexed to the Company's own stock. Section 815-40-15 provides that an entity should use a two- step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument's contingent exercise and settlement provisions.

We utilize a binomial option pricing model to compute the fair value of the derivative liability and to mark to market the fair value of the derivative liability at each balance sheet date. We record the change in the fair value of the derivative liability as other income or expense in the interim consolidated statements of operations.

The Company had derivative liabilities of $216,082 and $76,451 as January 31, 2023 and July 31, 2022, respectively.

***Revenue Recognition***

The Company's revenue recognition policy is to recognize revenue in accordance with ASC 606, "*Revenue from Contracts with Customers.*" The Company follows the five-step model provided by ASC Topic 606 in order to recognize revenue in the following manner: 1) Identify the contract; 2) Identify the performance obligations of the contract; 3) Determine the transaction price of the contract; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue. An entity recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company's revenue recognition policies remained unchanged as a result of the adoption of ASC 606, and there were no significant changes in business processes or systems.

***Advertising and Marketing***

Advertising and marketing costs are expensed as incurred in accordance with ASC 720-35, "*Advertising Costs*." We incurred advertising and marketing costs of $3,793 and $14,826 for the six months ended January 31, 2023 and 2022, respectively, which are included in selling, general and administrative expenses on the interim consolidated financial statements.

***Net Loss Per Common Share***

We determine basic loss per share and diluted income (loss) per share in accordance with the provisions of ASC 260, "*Earnings Per Share*." Basic loss per share excludes dilution and is computed by dividing earnings available to common stockholders by the weighted-average number of common shares outstanding for the period. The calculation of diluted loss per share is similar to that of basic earnings per share, except the denominator is increased, if the earnings are positive, to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been exercised.

***Stock-Based Compensation***

The Company accounts for stock-based compensation in accordance with ASC Topic 718, "*Compensation – Stock Compensation"* ("ASC 718") which establishes financial accounting and reporting standards for stock-based employee compensation. It defines a fair value-based method of accounting for an employee stock option or similar equity instrument. The Company accounts for compensation cost for stock option plans, if any, in accordance with ASC 718.

Stock-based payments, excluding restricted stock, are valued using a Black-Scholes option pricing model. Grants of stock-based payment awards issued to non-employees for services rendered have been recorded at the fair value of the stock-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Stock-based compensation expense is included in cost of goods sold or selling, general and administrative expenses, depending on the nature of the services provided, in the interim consolidated statements of operations. Stock-based payments issued to placement agents are classified as a direct cost of a stock offering and are recorded as a reduction in additional paid in capital.

The Company recognizes all forms of stock-based payments, including stock option grants, warrants and restricted stock grants, at their fair value on the grant date, which are based on the estimated number of awards that are expected to vest. See Note 12.

***Business Combinations***

We account for business combinations under the acquisition method of accounting. The acquisition method requires that the acquired assets and liabilities, including contingencies, be recorded at fair value determined on the acquisition date and that changes thereafter be reflected in income (loss). The estimation of fair values of the assets and liabilities assumed involves several estimates and assumptions that could differ materially from the actual amounts recorded. The results of the acquired businesses are included in our results from operations beginning from the day of acquisition.

***Income Taxes***

We use the asset and liability method of accounting for income taxes in accordance with Topic 740, *"Income Taxes".* Under this method, income tax expense is recognized for the amount of: (1) taxes payable or refundable for the current year and (2) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("*CARES Act*") was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 ("*2017 Tax Act*"). Corporate taxpayers may carryback net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.

In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the reporting periods presented.

 ****

 ****

***Recent Accounting Pronouncements***

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates ("ASU") through the date these interim consolidated financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective, that when adopted, will have a material impact on the interim consolidated financial statements of the Company.

**NOTE 2 – GOING CONCERN**

The accompanying interim consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern. The Company had net losses of $860,991 for the six months ended January 31, 2023 and $1,361,021 for its most recent fiscal year ended July 31, 2022. As of January 31, 2023, the Company has minimal cash and a significant working capital deficit. We have a history of losses, an accumulated deficit, have negative working capital and have not generated cash from our operations to support a meaningful and ongoing business plan. It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern.

In view of these matters, our ability to continue as a going concern is dependent upon the development, marketing and sales of a viable product to achieve a level of profitability. We intend to finance our future development activities and our working capital needs from the sale of private and public equity securities with additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. Although the Company believes in the viability of management's strategy to generate sufficient revenue, control costs and the ability to raise additional capital, there can be no assurances to that effect. Therefore, the accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue as a going concern.

**NOTE 3 – PROPERTY AND EQUIPMENT, NET**

Property and equipment, net consisted of the following at January 31, 2023 and July 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Equipment | $8923 | $8923 |
| Less: accumulated depreciation | (8923) | (8923) |
| Total property and equipment, net | $- | $- |

---

Depreciation expense for the six months ended January 31, 2023 and 2022 was $-0- and $232, respectively.

**NOTE 4 – INTANGIBLES, NET**

Intangibles, net consisted of the following at January 31, 2023 and July 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Intangible assets under development | $663655 | $559103 |
| Capitalized costs of patents | 128794 | 137798 |
| Capitalized costs of website | 8785 | 8785 |
| Less: accumulated amortization | (20194) | (17333) |
| Total intangibles, net | $781040 | $688353 |

---

Amortization expense for the six months ended January 31, 2023 and 2022 was $11,865 and $5,342, respectively. Amortization expense for the six months ended January 31, 2023 includes $8,279 related to the abandonment of a patent during the period.

Intangibles are amortized over their estimated useful lives of two (2) to twenty (20) years. As of January 31, 2023, the weighted average remaining useful life of intangibles being amortized was approximately eighteen (18) years. We expect the remaining estimated aggregate amortization expense to be as follows:

---

| | |
|:---|:---|
| 2023 | $3586 |
| 2024 | 6440 |
| 2025 | 6440 |
| 2026 | 6440 |
| 2027 | 6440 |
| Thereafter | 88039 |
| Total expected amortization expense | $117385 |

---

**NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consisted of the following at January 31, 2023 and July 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Accounts payable | $156465 | $119725 |
| Accrued interest expense | 81208 | 83248 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 237673 | 202973 |
| Accounts payable, related party | 333231 | 267765 |
| Accrued expenses, related party | 535250 | 373550 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses, related party | 868481 | 641315 |
| Total accounts payable and accrued expenses | $1106154 | $844288 |

---

**NOTE 6 – PAYROLL RELATED LIABILITIES**

Payroll related liabilities consisted of the following at January 31, 2023 and July 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Accrued officers' payroll | $1582248 | $1440364 |
| Payroll taxes payable | 12070 | 12070 |
| Total payroll related liabilities | $1594318 | $1452434 |

---

**NOTE 7 – DEBT**

We had the following debt obligations reflected at their respective carrying values on our interim consolidated balance sheets as of January 31, 2023 and July 31, 2022:

SCHEDULE OF DEBT OBLIGATIONS

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| 5% Convertible promissory notes | $275000 | $325000 |
| Note payable to Acorn Management Partners, LLC | 50000 | 50000 |
| Note payable to AJB Capital Investments, LLC | 600000 | 600000 |
| &nbsp;&nbsp;&nbsp;Total debt obligations | 925000 | 975000 |
| Less debt discount |  | (194395) |
| Less current portion | (925000) | (780605) |
| Long-term debt | $- | $- |

---

***5% Convertible Promissory Notes***

On various dates during the month of March 2018, we issued a series of 5% Convertible Promissory Notes (collectively, the "5% Notes") totaling $750,000 in net proceeds. We incurred no costs related to the issuance of the 5% Notes. The 5% Notes bear interest at the rate of five percent (5%) per annum, compounded annually and matured one-year from the date of issuance. At January 31, 2023 and July 31, 2022, accrued but unpaid interest on the 5% Notes was $81,208 and $83,248, respectively, which is included in "accounts payable and accrued expenses" on our interim consolidated balance sheets.

The 5% Notes are convertible Into common shares of the Company at a fixed ratio of two shares of common stock per dollar amount of the face value of the note. The principal terms under which the 5% Notes may be converted into common stock of the Company are as follows:

● At the option of the holder, the outstanding principal amount of the note, and any accrued but unpaid interest due, may be converted into the Company's common stock at any time prior to the maturity date of the note.

● The outstanding principal amount of the note, and any accrued but unpaid interest due, will automatically be converted into the Company's common stock if at any time prior to the maturity date of the note, the Company concludes a sale of equity securities in a private offering resulting in gross proceeds to the Company of at least $1,000,000.

5% Notes with a face amount of $50,000 and related accrued interest of $10,363 were converted into shares of our common stock during the six months ended January 31, 2023 or. There were no 5% Notes converted into shares of our common stock during our latest fiscal year ending July 31, 2022. At January 31, 2023, 5% Notes with a face amount of $275,000 and related accrued interest expense of $73,789 are currently in default and are not convertible under the conversion terms. Management is currently negotiating amendments to the notes in default to extend the maturity dates of such notes and to encourage note conversions.

***Note Payable to Acorn Management Partners, LLC***

On August 11, 2020 we agreed to repurchase 1,000,000 shares of our common stock from Acorn Management Partners, LLC ("AMP"). As consideration for the share repurchase, we issued a $50,000 promissory note bearing interest a 6.0% per annum and due one-year from the date of issuance (the "AMP Note"). The AMP Note was subsequently amended to extend the maturity date to March 31, 2023. In the event we default under the terms of the AMP Note, we are required to deliver 1,000,000 shares of our common stock back to AMP in full satisfaction of the obligation. The purchased shares were delivered by AMP directly to the transfer agent on September 8, 2020 and immediately cancelled. Accrued but unpaid interest on the AMP Note at January 31, 2023 and July 31, 2022 was $7,419 and $5,919, respectively, which is included in "accounts payable and accrued expenses" on our interim consolidated balance sheets.

***Note Payable to AJB Capital Investments, LLC***

On February 2, 2021, we entered into a Securities Purchase Agreement with AJB Capital Investments, LLC ("AJB Capital"), pursuant to which AJB Capital purchased a Promissory Note (the "AJB Note 1") in the principal amount of $360,000 for an aggregate purchase price of $320,400. The AJB Note 1 accrued interest at the rate of ten percent (10%) per annum and matured on August 2, 2021. At our option, the maturity date of the note was extended for six (6) months. Upon extension of the maturity date, the AJB Note 1 interest rate increased to twelve percent (12%) per annum during the extension period. We recorded a debt discount of $59,300 related to original issue discount and issuance cost of the note. The principal balance of the AJB Note 1 was paid in full on February 9, 2022 with a portion of the net proceeds from the issuance of a new note to AJB Capital on such date.

On February 9, 2022, we entered into a Securities Purchase Agreement with AJB Capital, pursuant to which AJB Capital purchased a Promissory Note (the "AJB Note 2") in the principal amount of $600,000 for an aggregate purchase price of $534,000. The AJB Note 2 accrues interest at the rate of ten percent (10%) per annum and matures on February 9, 2023. We recorded a debt discount of $96,000 related to original issue discount and issuance cost of the note.

In the event of default, the AJB Note 2 may be converted into shares of the Company's common stock at a conversion price equal to the lesser of the lowest trading price (i) during the previous twenty (20) trading day period ending on the issuance date of the note, or (ii) during the previous twenty (20) trading day period ending on the date of conversion of the note. We recorded a debt discount of $192,886 related to the conversion feature of the AJB Note 2.

As additional consideration for the purchase of the AJB Note 2, we issued AJB Capital 1,500,000 common stock purchase warrants (the "Warrants") giving AJB Capital the option to purchase up to 1,500,000 shares of our common stock at a price of $0.10 per share. At the option of AJB Capital, 1,000,000 of the Warrants may be exercised on a "cashless" basis pursuant to a formula included in the Warrant. The $99,905 grant date fair value of the Warrants was recorded as a debt discount.

Total unamortized debt discount related to the AJB Capital notes at January 31, 2023 and July 31, 2022 was $-0- and $194,395, respectively. During the six months ended January 31, 2023 and 2022, amortization of the debt discount was $194,395 and $90,000, respectively. Debt discount is included as a component of interest expense in the interim consolidated statements of operations.

**NOTE 8 – DERIVATIVE LIABILITY**

On February 2, 2021, we entered into a Securities Purchase Agreement with AJB Capital Investments, LLC ("AJB Capital"), pursuant to which AJB Capital purchased a Promissory Note (the "AJB Note 1") in the principal amount of $360,000 for an aggregate purchase price of $320,400. The note was fully repaid on February 9, 2022.

On February 9, 2022, we entered into a new Securities Purchase Agreement with AJB Capital, pursuant to which AJB Capital purchased a Promissory Note (the "AJB Note 2") in the principal amount of $600,000 for an aggregate purchase price of $534,000 (See Note 7).

In the event of default, the AJB Capital notes may be converted into shares of the Company's common stock. We identified certain conversion features embedded in the AJB Capital notes that represent derivative liabilities.

The following table summarizes the changes in fair value, including transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended January 31, 2023:

SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES

---

| | |
|:---|:---|
|  | **Fair Value**<br> **Measurement** <br> **Using Level 3** <br> **Inputs** |
| Balance, July 31, 2022 | $76451 |
| Change in fair value of derivative liability | 139631 |
| Balance, January 31, 2023 | $216082 |

---

During the six months ended January 31, 2023 and 2022, the fair value of the derivative feature of the AJB Capital notes was calculated using the following range of assumptions:

SCHEDULE OF FAIR VALUE ASSUMPTIONS OF DERIVATIVE FEATURE

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **January 31, 2022** |
| Expected volatility of underlying stock | 105.65-126.40% | 70.4-100.34% |
| Expected term (in years) | .02 - .27 | .01 - .25 |
| Risk-free interest rate | 4.06-4.58% | 0.04% |
| Dividend yield |  |  |

---

As of January 31, 2023 and July 31, 2022, the derivative liability related to the AJB Capital notes was $216,082 and $76,451, respectively. For the six months ended January 31, 2023 and 2022, we recorded expense of $139,631and income of $59,091, respectively, related to the change in fair value of the derivative liability.

**NOTE 9 – INCOME TAXES**

A reconciliation of the provision for income taxes as reported, and the amount computed by multiplying net loss by the federal statutory rate of 21% for the six months ended January 31, 2023 and 2022 are as follows:

SCHEDULE OF RECONCILIATION OF PROVISION FOR INCOME TAXES

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **January 31, 2022** |
| Federal income tax benefit computed at the statutory rate | $(180808) | $(169843) |
| Increase resulting from: |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 42678 | 70725 |
| &nbsp;&nbsp;&nbsp;Derivatives | 73771 | 25391 |
| &nbsp;&nbsp;&nbsp;Valuation allowance | 64357 | 73526 |
| &nbsp;&nbsp;&nbsp;Other | 2 | 201 |
| Income tax benefit, as reported | $- | $- |

---

The components of the net deferred tax asset as of January 31, 2023 and July 31, 2022 are as follows:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Deferred tax assets: |  |  |
| &nbsp;&nbsp;&nbsp;Net operating loss carryovers | $838208 | $773851 |
| &nbsp;&nbsp;&nbsp;Valuation allowance | (838208) | (773851) |
| Net deferred tax asset, as reported | $- | $- |

---

In assessing the realizable value of deferred tax assets, management considers whether it is more likely than not that some portion or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon generation of future taxable income during the periods in which these temporary differences become tax deductible. Based on management's assessment of objective and subjective evidence, we have concluded at this time it is more likely than not that all of our deferred tax asset will not be realized and we have provided a valuation allowance for the entire amount of the deferred tax asset. At July 31, 2022, our most recently completed fiscal year, we have approximately $3.59 million in federal and state net operating loss carryovers that begin expiring in fiscal 2037.

We conduct business solely in the United States and file income tax returns in the United States federal jurisdiction as well as in the states of Tennessee and Colorado. The taxable years ended July 31, 2022, 2021, 2020, 2019 and 2018 remain open to examination by the taxing jurisdictions to which we are subject.

The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise's financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the Company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits." A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise's potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as "Other expenses – Interest expense" in the consolidated statements of operations. Penalties would be recognized as a component of "General and administrative."

No material interest or penalties on unpaid tax were recorded during the six months ended January 31, 2023 and 2022. As of January 31, 2023 and July 31, 2022, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next fiscal year.

**NOTE 10 – RELATED PARTY TRANSACTIONS**

To continue operations and meet operating cash requirements, we have periodically relied on short term loans from related parties, primarily shareholders, until such time as our cash flow from operations meets our cash requirements, or we are able to obtain adequate financing through sales of our equity securities and/or traditional debt financing. There is no formal written commitment for continued support by shareholders or others. Amounts loaned primarily relate to amounts paid to vendors. The loans are considered temporary in nature and have not been formalized by any written agreement. As of January 31, 2023 and July 31, 2022, related parties were owed $333,231 and $267,765, respectively, which are included in accounts payable and accrued expenses, related party on the interim consolidated balance sheets – see Note 5. The amounts owed are payable on demand and carry no interest. The amounts and terms of the related party loans may not necessarily be indicative of the amounts and terms that would have been incurred had comparable transactions been entered into with independent third parties.

Effective May 1, 2021, we entered into a Non-Employee Chief Executive Officer Engagement Agreement (the "Contract CEO Agreement") with Platinum Equity Advisors, LLC ("Platinum Equity"), a related party, to provide the services of our CEO and Chairman of the Board of Directors. At January 31, 2023 and July 31, 2022, we owed Platinum Equity $535,250 and $373,550, respectively, under the terms of the Contract CEO Agreement. The amount owed is included in accounts payable and accrued expenses, related party on the interim consolidated balance sheets – see Note 5.

**NOTE 11 – COMMON STOCK**

At January 31, 2023 and July 31, 2022, we had 42,830,061 and 42,304,673 shares of common stock outstanding, respectively. We issued 404,662 shares for services and 120,726 shares for the conversion of debt and related accrued interest during the six months ended January 31, 2023. During the fiscal year ended July 31, 2022, we issued 2,186,666 shares of common stock, of which 1,250,000 shares were issued upon final settlement of a securities purchase agreement, 666,666 shares were issued pursuant to a debt settlement and amendment agreement, 170,000 shares were issued for services, and 100,000 shares were issued for the vesting of an employee stock award.

On August 26, 2022, we executed a consulting agreement with G. Shayne Bench, individually, and Bucuti Investments, LLC, or assignee ("Bench") to provide business advisory services in analyzing, structuring, negotiating and effecting business combinations, and serving on our Board of Directors. Pursuant to the terms of the agreement, we provided Bench a one (1) year restricted stock award of 846,093 shares. The restricted stock award vest ratably, on a monthly basis, at the end of each month of completed service. Vested common shares are issued on a quarterly basis in accordance with the Company's quarterly reporting periods. On November 8, 2022, we issued 154,662 shares of our common stock to Bench at an estimated value of $0.0135 per share for shares vested through our fiscal quarter ended October 31, 2022.

On January 20, 2023, we issued 120,726 shares of common stock to the holder of a $50,000 5% Convertible Promissory Note (the "Note") in exchange for the Note plus accrued interest of $10,363 through the conversion date. Under the terms of the Note, the shares were issued at a conversion price of $0.50 per share.

**NOTE 12 – STOCK-BASED COMPENSATION**

Our stock-based compensation programs are long-term retention awards that are intended to attract, retain, and provide incentives for employees, officers and directors, and to align stockholder and employee interest. We utilize grants of both stock options and warrants and restricted stock to achieve those goals.

**<u>Summary of Stock Options and Warrants</u>**

During the six months ended January 31, 2023, we recorded $128,059 of compensation expense, net of capitalized expense of $39,316, related to stock options and warrants. During the six months ended January 31, 2022, we recorded $282,887 of compensation expense, net of capitalized expense of $39,316, related to stock options and warrants. We granted no stock options or warrants during the six months ended January 31, 2023 or 2022.

The following table summarizes our options and warrant activity for the six months ended January 31, 2023 and fiscal year ended July 31, 2022:

SUMMARY OF OPTIONS AND WARRANTS ACTIVITY

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **January 31, 2023** | **January 31, 2023** | **July 31, 2022** | **July 31, 2022** |
|  | **Number of Options and Warrants** | **Weighted Average Exercise Price** | **Number of Options and Warrants** | **Weighted Average Exercise Price** |
| Balance at beginning of year | 7350000 | $1.21 | 7350000 | $1.21 |
| &nbsp;&nbsp;&nbsp;Granted |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Exercised | - | - | - | - |
| Balance at end of period | 7350000 | $1.21 | 7350000 | $1.21 |
| Options and warrants exercisable | 6233333 | $1.37 | 5800000 | $1.45 |

---

**<u>Summary of Restricted Stock Grants</u>**

During the six months ended January 31, 2023 and 2022, we recorded compensation expense related to restricted stock grants of $22,103 and $14,583, respectively. The grant date fair value of restricted stock awards during the six months ended January 31, 2023 was $76,422. There were no restricted stock grants during the year ended July 31, 2022.

The following table summarizes our restricted stock activity for the six months ended January 31, 2023 and fiscal year ended July 31, 2022:

SCHEDULE OF RESTRICTED STOCK ACTIVITY

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Balance at beginning of period | 100000 | 200000 |
| &nbsp;&nbsp;&nbsp;Granted | 2846093 |  |
| &nbsp;&nbsp;&nbsp;Released |  | (100000) |
| &nbsp;&nbsp;&nbsp;Forfeited | - | - |
| Balance at end of period | 2946093 | 100000 |

---

**NOTE 13 – COMMITMENTS AND CONTINGENCIES**

***Employment and Consulting Agreements***

Effective May 1, 2021, we entered into a Non-Employee Chief Executive Officer Engagement Agreement (the "Contract CEO Agreement") with Platinum Equity Advisors, LLC ("Platinum") to provide the services of Scott M. Boruff as Chief Executive Officer and Chairman of the Board of Directors of the Company for a term of three (3) years. As compensation for the services, the Company shall pay Platinum an annual base fee of $323,400. If the Contract CEO Agreement is terminated by us without cause or by Platinum for good reason, we are obligated to pay Platinum severance equal to one (1) year's base fee and any other earned but unpaid compensation. In addition, if at any time during the term of the Contract CEO Agreement Platinum is terminated by us without cause within two years after a Change in Control of our company, or in the 90 days prior the Change in Control at the request of the acquiror, we are obligated to pay Platinum an amount equal to 2.99 times the annual base fee. "Change in Control" is defined in the Contract CEO Agreement to mean the acquisition by any person of beneficial ownership of our securities representing greater than 50% of the combined voting power of our then outstanding voting securities. Platinum is eligible for equity awards as approved by the Board of Directors as defined in the agreement.

On September 1, 2020, in connection with the appointment of Susan A. Reyes, M.D. as Chief Medical Officer of the Company, the Company and Dr. Reyes entered into an employment agreement (the "Reyes Employment Agreement") with an initial term of three (3) years. As compensation for her services, the Company shall pay Dr. Reyes an annual base salary of $52,000. The base salary shall be accrued until the Company obtains funding of at least $1,000,000, or has reported $10,000,000 in revenue, whichever occurs first. In the event Dr. Reyes' employment with the Company is terminated without cause, Dr. Reyes shall be entitled to a severance payment equal to her base salary for one (1) full year. If Dr. Reyes is terminated without cause within two (2) years of a change in control upon request of the acquiror, Dr. Reyes shall be entitled to a severance payment in an amount equal to 2.99 times the annualized base salary she is then earning. In addition, Dr. Reyes is eligible for equity awards as approved by the Board of Directors as defined in the agreement.

On June 15, 2020, in connection with the appointment of Kenneth M. Greenwood as Chief Technology Officer of the Company, the Company and Mr. Greenwood entered into an employment agreement (the "Greenwood Employment Agreement") with an initial term of three (3) years. As compensation for his services, the Company shall pay Mr. Greenwood an annual base salary of $257,000. The base salary shall be accrued until the Company obtains funding of $1,000,000 in excess of funding used for inventory purchases, or has $1,000,000 in revenue, whichever occurs first. In the event Mr. Greenwood's employment with the Company is terminated without cause, Mr. Greenwood shall be entitled to a severance payment equal to his base salary for one (1) full year. If Mr. Greenwood is terminated without cause within two (2) years of a change in control upon request of the acquiror, Mr. Greenwood shall be entitled to a severance payment in an amount equal to 2.99 times the annualized base salary he is then earning. In addition, Mr. Greenwood is eligible for equity awards as approved by the Board of Directors as defined in the agreement.

On October 8, 2019, in connection with the appointment of Charles B. Lobetti, III as Chief Financial Officer of the Company, the Company and Mr. Lobetti entered into an employment agreement (the "Lobetti Employment Agreement") with an initial term of three (3) years and is currently on a month-to-month basis. Pursuant to a modification of the Lobetti Employment Agreement effective May 1, 2020, the Company shall pay Mr. Lobetti an annual base salary of $104,000 per year as compensation for his services. In the event Mr. Lobetti's employment with the Company is terminated without cause, Mr. Lobetti shall be entitled to a severance payment equal to his base salary for one (1) full year. If Mr. Lobetti is terminated without cause within two (2) years of a change in control upon request of the acquiror, Mr. Lobetti shall be entitled to a severance payment in an amount equal to 2.99 times the annualized base salary he is then earning. In addition, Mr. Lobetti is eligible for equity awards as approved by the Board of Directors as defined in the agreement.

***Litigation***

 ****

From time to time, the Company may become involved in litigation relating to claims arising in the ordinary course of the business. There are no claims or actions pending or threatened against the Company that, if adversely determined, would in the Company's management's judgment have a material adverse effect on the Company.

**NOTE 14 – SUBSEQUENT EVENTS**

On February 10, 2023, we issued 254,446 shares of common stock to the holder of a $100,000 5% Convertible Promissory Note (the "Note") in exchange for the Note plus accrued interest of $27,223 through the conversion date. Under the terms of the Note, the shares were issued at a conversion price of $0.50 per share.

We evaluate subsequent events and transactions that occur after the balance sheet date for the period presented and up to the issuance date of the financial statements. Based on our review, we did not identify any subsequent events other than those described above that would require adjustment to or disclosure in the interim consolidated financial statements.

**Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

THE FOLLOWING DISCUSSION OF OUR PLAN OF OPERATION AND RESULTS OF OPERATIONS SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND RELATED NOTES TO THE FINANCIAL STATEMENTS INCLUDED ELSEWHERE IN THIS REPORT. THIS DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS THAT RELATE TO FUTURE EVENTS OR OUR FUTURE FINANCIAL PERFORMANCE. THESE STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE OUR ACTUAL RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE RISKS AND OTHER FACTORS INCLUDE, AMONG OTHERS, THOSE LISTED UNDER "FORWARD-LOOKING STATEMENTS" AND "RISK FACTORS" AND THOSE INCLUDED ELSEWHERE IN THIS REPORT.

This following discussion summarizes the significant factors affecting the interim consolidated financial statements, financial condition, liquidity, and cash flows of Healthcare Integrated Technologies, Inc, for the six months ended January 31, 2023 and 2022. The discussion and analysis should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K for the year ended July 31, 2022 as filed with the SEC on September 23, 2022.

**<u>Executive Overview</u>**

Healthcare Integrated Technologies, Inc. and its subsidiaries is a healthcare technology company based in Knoxville, Tennessee. We are creating a diversified spectrum of healthcare technology solutions to integrate and automate the continuing care, home care and professional healthcare spaces.

Our initial product, SafeSpace™ with AI Vision™, is an ambient fall detection solution designed for continuing care communities and at home use. SafeSpace includes hardware devices utilizing RGB, radar and other sensor technology coupled with our internally developed software to effectively monitor a person remotely. In continuing care communities, SafeSpace detects resident falls and generates alerts to a centralized, intelligent dashboard without the use of wearable devices or any action by the resident. In the home, SafeSpace detects falls and sends alerts directly to designated individuals.

In addition to SafeSpace, we are creating a home concierge healthcare service application to provide a virtual assisted living experience for seniors, recently released postoperative patients, and others. The concierge application will enable the consumer to obtain home healthcare services and health and safety monitoring equipment to improve quality of life. We are also working to develop a fully integrated solution for the professional healthcare community that integrates electronic health records, remote patient monitoring, telehealth, and other items where integration is beneficial.

***Strategy***

Our mission is to grow a profitable healthcare technology company by focusing on our core product, continuing the development of our proprietary software, and developing new uses and product lines for our technology. Our management team is focused on maintaining the financial flexibility and assembling the right complement of personnel and outside consultants required to successfully execute our mission.

 ****

***Financial and Operating Results***

**<u>Results of Operations</u>**

***Three Months Ended January 31, 2023 Compared to the Three Months Ended January 31, 2022***

***Revenues***

Our healthcare technology business is not currently producing revenue as we continue to develop, refine and evaluate our products.

***Selling, General and Administrative Expenses***

The table below presents a comparison of our selling, general and administrative expenses for the three months ended January 31, 2023 and 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended**<br> **January 31,** | **For the Three Months Ended**<br> **January 31,** | | |
|  | **2023** | **2022** | **$ Variance** | **%Variance** |
| Officers' salaries | $124169 | $124252 | $(83) |  |
| Stock-based compensation | 92843 | 148735 | (55892) | (38)% |
| Professional fees | 27411 | 33338 | (5927) | (18)% |
| Advertising and marketing |  | 4122 | (4122) |  |
| Depreciation and amortization | 9776 | 2860 | 6916 | 242% |
| Other | 962 | 957 | 5 | 1% |
| &nbsp;&nbsp;&nbsp;**Total** | $255161 | $314264 | $(59103) | (19)% |

---

*Stock-based Compensation–-* Stock-based compensation expense decreased $55,892, or 38%, from the same period in the prior year. The decrease results from a 2023 reduction in the amortization of the grant date fair value of employee stock options granted to our CEO and a restricted stock grant to our CFO, which was partially offset by the expense related to the issuance of new shares and restricted stock grants to outside consultants.

*Professional Fees -* Professional fees decreased $5,927, or 18%, over the 2022 amount. In 2023, fees paid to outside consultants decreased by $6,870, which was partially offset by a small net increase in other professional fees such as accounting, legal, transfer agent and Edgar processing fees.

*Advertising and Marketing -* Advertising and marketing expense decreased $4,122 over 2022. The decrease is primarily due to the elimination of a contract sales and marketing representative in 2023.

 

*Depreciation and Amortization* - Depreciation and amortization expense increased $6,916 over the same period in the prior year. The increase primarily results from the abandonment of a patent in 2023 which was partially offset by declining depreciation and amortization expense as older assets become fully expensed and/or disposed of.

 ****

***Other Income (Expense)***

The table below presents a comparison of our other income (expense) for the three months ended January 31, 2023 and 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended**<br> **January 31,** | **For the Three Months Ended**<br> **January 31,** | | |
|  | **2023** | **2022** | **$ Variance** | **%Variance** |
| Interest expense | $(119832) | $(106253) | $(13579) | 13% |
| Change in fair value of derivative liability | 156894 | 26794 | 130100 | 486% |
| &nbsp;&nbsp;&nbsp;**Total** | $37062 | $(79459) | $116521 | (147)% |

---

*Interest Expense* - Interest expense increased $13,579, or 13%, over the same period in the prior year. The increase is primarily due to increased amortization of the debt discount associated with the new AJB Note 2 and an increase in the monthly coupon interest on the larger principal balance of the AJB Note 2.

*Change in Fair Value of Derivative Liability* - The change in the fair value of the derivative liabilities associated with our AJB Capital notes reflect a current period gain of $156,894 as compared to a gain of $26,794 in the prior period. The current period gain resulted from a decrease in the fair value of the derivative liability on the new AJB Capital note during the current three month period.

***Six Months Ended January 31, 2023 Compared to the Six Months Ended January 31, 2022***

***Revenues***

Our healthcare technology business is not currently producing revenue as we continue to develop, refine and evaluate our products.

***Selling, General and Administrative Expenses***

The table below presents a comparison of our selling, general and administrative expenses for the six months ended January 31, 2023 and 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Six Months Ended**<br> **January 31,** | **For the Six Months Ended**<br> **January 31,** | | |
|  | **2023** | **2022** | **$ Variance** | **%Variance** |
| Officers' salaries | $248293 | $256008 | $(7715) | (3)% |
| Stock-based compensation | 163912 | 297470 | (133558) | (45)% |
| Professional fees | 58939 | 76842 | (17903) | (23)% |
| Advertising and marketing | 3793 | 14826 | (11033) | (74)% |
| Depreciation and amortization | 11865 | 5573 | 6292 | 113% |
| Other | 1840 | 4642 | (2802) | (60)% |
| &nbsp;&nbsp;&nbsp;**Total** | $488642 | $655361 | $(166719) | (25)% |

---

*Officers' Salaries -* Officers' salaries, net of capitalized amounts, decreased $7,715 from 2022, or 3%. The decrease resulted from a bonus being paid to our CFO in 2022.

*Stock-based Compensation -* Stock-based compensation expense decreased $133,558, or 45%, from the same period in the prior year. The decrease results from a 2023 reduction in the amortization of the grant date fair value of employee stock options granted to our CEO and a restricted stock grant to our CFO, which was partially offset by the expense related to the issuance of new shares and restricted stock grants to outside consultants.

 

*Professional Fees -* Professional fees decreased $17,903, or 23%, over the 2022 amount. In 2023, fees paid to outside consultants decreased $16,990 and accounting fees decreased $2,305 over the same period in the prior year. The decreases in consulting and accounting fees were partially offset by small increases in legal, transfer agent and Edgar processing fees.

*Advertising and Marketing -* Advertising and marketing expense decreased $11,033, or 74%, over 2022. The decrease is primarily due to the elimination of a contract sales and marketing representative in 2023.

 

*Depreciation and Amortization* - Depreciation and amortization expense increased $6,292 over the same period in the prior year. The increase primarily results from the abandonment of a patent which was partially offset by declining depreciation expense as older assets become fully depreciated and/or disposed of.

*Other* - Other expense decreased $2,802, or 60%, over the same period in the prior year. The decrease primarily relates to lower travel and entertainment related expenses in 2023.

***Other Income (Expense)***

The table below presents a comparison of our other income (expense) for the six months ended January 31, 2023 and 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Six Months Ended**<br> **January 31,** | **For the Six Months Ended**<br> **January 31,** | | |
|  | **2023** | **2022** | **$ Variance** | **%Variance** |
| Interest expense | $(232718) | $(212506) | $(20212) | (10)% |
| Change in fair value of derivative liability | (139631) | 59091 | (198722) | (336)% |
| &nbsp;&nbsp;&nbsp;**Total** | $(372349) | $(153415) | $(218934) | 143% |

---

*Interest Expense* - Interest expense increased $20,212, or 10%, over the same period in the prior year. The increase is primarily due to increased amortization of the debt discount associated with the new AJB Note 2 and an increase in the monthly coupon interest on the larger principal balance of the AJB Note 2.

*Change in Fair Value of Derivative Liability* - The change in the fair value of the derivative liabilities associated with our AJB Capital notes reflect a current period loss of $139,631 as compared to a gain of $59,091 in the prior period. The current period loss resulted from an increase in the fair value of the derivative liability on the new AJB Capital note during the six month period.

**<u>Liquidity and Capital Resources</u>**

***Working Capital***

The following table summarizes our working capital for the interim period ended January 31, 2023 and fiscal year ended July 31, 2022:

---

| | | |
|:---|:---|:---|
|  | **January 31, 2023** | **July 31, 2022** |
| Current assets | $35355 | $37667 |
| Current liabilities | (3841554) | (3153778) |
| Working capital deficiency | $(3806199) | $(3116111) |

---

Current assets for the interim period ended January 31, 2023 decreased $2,312 as compared to the fiscal year ended July 31, 2022. The decrease is due to a decrease in cash and cash equivalents and the amortization of prepaid expenses.

Current liabilities for the interim period ended January 31, 2023 increased $687,776 as compared to the fiscal year ended July 31, 2022. The increase is due to increases in accounts payable and accrued expenses, short-term loans from related parties to meet cash flow needs, the continuing accrual of officer's compensation, new proceeds from the AJB Note 2 and an increase in the fair value of derivative liabilities. The increases were partially offset by a decrease in convertible notes due to note conversions to common stock during the period.

 ****

***Net Cash Used by Operating Activities***

We currently do not have a revenue source and will continue to have negative cash flow from operations for the near future. The factors in determining operating cash flows are largely the same as those that affect net earnings, except for non-cash expenses such as depreciation and amortization, stock-based compensation, amortization of debt discount, and changes in fair value of assets and liabilities, which affect earnings but do not affect operating cash flow. Net cash used by operating activities was $60,891 for the six months ended January 31, 2023 as compared to $103,868 for the six months ended January 31, 2022. The $42,977 decrease in cash used by operating activities during 2023 is primarily attributable to accrued interest expense and an overall effort by management to reduce operating costs.

 ****

***Net Cash Used by Investing Activities***

Net cash used by investing activities was $5,610 and $25,022 for the six months ended January 31, 2023 and 2022, respectively. The amount is comprised of cash paid for the filing of patent applications and for the development of software for our internal use.

***Net Cash Provided by Financing Activities***

Net cash provided by financing activities was $65,466 for the six months ended January 31, 2023, which represents a $52,109 decrease over the same period of 2022. The decrease from 2022 is primarily due to a $25,000 decline in proceeds from stock subscriptions and a net cash decrease of $27,109 from related party loan and repayment transactions.

At this time, we cannot provide investors with any assurance that we will be able to obtain sufficient funding from debt financings and/or the sale of our equity securities to meet our obligations over the next twelve months. We are likely to continue using short-term loans from management to meet our short-term funding needs. We have no material commitments for capital expenditures as of January 31, 2023.

**<u>Going Concern Qualification</u>**

We have a history of losses, an accumulated deficit, a negative working capital and have not generated cash from operations to support a meaningful and ongoing business plan. Our Independent Registered Public Accounting Firm has included a "Going Concern Qualification" in their report for the years ended July 31, 2022 and 2021. The foregoing raises substantial doubt about the Company's ability to continue as a going concern. We intend on financing our future activities and working capital needs from the sale of private and/or public equity securities with additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. There is no guarantee that additional capital or debt financing will be available when and to the extent required, or that if available, it will be on terms acceptable to us. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The "Going Concern Qualification" might make it more difficult to raise capital.

**<u>Critical Accounting Policies and Estimates</u>**

Our interim consolidated financial statements and related public financial information are based on the application of U.S. GAAP. U.S. GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to U.S. GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note 1 of our interim consolidated financial statements.

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in our July 31, 2022 Annual Report.

We believe the following critical policies impact our more significant judgments and estimates used in preparation of our financial statements.

***Use of Estimates***

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We base our estimates on experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate our estimates and assumptions on a regular basis and actual results may differ from those estimates.

***Impairment of Long-Lived Assets***

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, we estimate fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

 ****

***Intangible Assets***

Intangible assets consist of patents, our website and the costs of software developed for internal use. Certain payroll and stock-based compensation costs incurred are allocated to the intangible assets. We determine the amount of costs to be capitalized based on the time spent by employees or outside contractors on the projects. Intangible assets are amortized over their expected useful life on a straight-line basis. We evaluate the useful lives of these assets on an annual basis and test for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. If the estimate of an intangible asset's remaining life is changed, the remaining carrying value of the intangible asset is amortized prospectively over the revised remaining useful life. We did not recognize any impairment losses during any of the periods presented.

***Fair Value of Financial Instruments***

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and borrowings. The fair value of current financial assets and current financial liabilities approximates their carrying value because of the short-term maturity of these financial instruments.

***Derivative Liability***

Options, warrants, convertible notes, or other contracts, if any, are evaluated to determine if those contracts, or embedded components of those contracts, qualify as derivatives to be separately accounted for in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 815, *"Derivatives and Hedging,"* (paragraph 815-10-05-4 and Section 815-40-25). The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. The change in fair value is recorded in the consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise, or cancellation and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated, and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

The Company adopted Section 815-40-15 of the FASB ASC *("Section 815-40-15")* to determine whether an instrument (or an embedded feature) is indexed to the Company's own stock. Section 815-40-15 provides that an entity should use a two- step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument's contingent exercise and settlement provisions.

We utilize a binomial option pricing model to compute the fair value of the derivative liability and to mark to market the fair value of the derivative at each balance sheet date. We record the change in the fair value of the derivative as other income or expense in the consolidated statements of operations.

***Revenue Recognition***

The Company's revenue recognition policy is to recognize revenue in accordance with ASC 606, "*Revenue from Contracts with Customers.*" The Company follows the five-step model provided by ASC Topic 606 in order to recognize revenue in the following manner: 1) Identify the contract; 2) Identify the performance obligations of the contract; 3) Determine the transaction price of the contract; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue. An entity recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. The Company's revenue recognition policies remained unchanged as a result of the adoption of ASC 606, and there were no significant changes in business processes or systems.

***Stock-based Compensation***

The Company accounts for stock-based compensation in accordance with ASC Topic 718, "*Compensation – Stock Compensation"* ("ASC 718") which establishes financial accounting and reporting standards for stock-based employee compensation. It defines a fair value-based method of accounting for an employee stock option or similar equity instrument. The Company accounts for compensation cost for stock option plans, if any, in accordance with ASC 718.

Stock-based payments, excluding restricted stock, are valued using a Black-Scholes option pricing model. Grants of stock-based payment awards issued to non-employees for services rendered have been recorded at the fair value of the stock-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Stock-based compensation expenses are included in cost of goods sold or selling, general and administrative expenses, depending on the nature of the services provided, in the consolidated statements of operations. Stock-based payments issued to placement agents are classified as a direct cost of a stock offering and are recorded as a reduction in additional paid in capital.

The Company recognizes all forms of stock-based payments, including stock option grants, warrants and restricted stock grants, at their fair value on the grant date, which are based on the estimated number of awards that are expected to vest.

 ****

***Business Combinations***

We account for business combinations under the acquisition method of accounting. The acquisition method requires that the acquired assets and liabilities, including contingencies, be recorded at fair value determined on the acquisition date and that changes thereafter be reflected in income (loss). The estimation of fair values of the assets and liabilities assumed involves estimates and assumptions that could differ materially from the actual amounts recorded. The results of the acquired businesses are included in our results from operations beginning from the day of acquisition.

**<u>Capital Resources</u>**

We had no material commitments for capital expenditures as of January 31, 2023.

**<u>Off-Balance Sheet Arrangements</u>**

The Company has no off-balance sheet arrangements as of January 31, 2023.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

We do not hold any market risk sensitive instruments. We consider our interest rate risk exposure to be minimal as a result of fixing interest rates on 100% of our debt. At January 31, 2023, there was no floating rate debt that would expose us to market fluctuations in interest rates.

**Item 4. CONTROLS AND PROCEDURES.**

**<u>Disclosure Controls and Procedures</u>**

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended, at the end of the period covered by this report (the "Evaluation Date"). In conducting its evaluation, management considered the material weaknesses described below in Management's Report on Internal Control over Financial Reporting.

Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of the Evaluation Date we did not maintain disclosure controls and procedures that were effective in providing reasonable assurances that information required to be disclosed in our reports filed under the Securities Exchange act of 1934 was recorded, processed, summarized and reported within the time periods prescribed by SEC rules and regulations, and that such information was accumulated and communicated to our management to allow timely decisions regarding required disclosure.

Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

**<u>Changes in Internal Control over Financial Reporting</u>**

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS.**

None.

**Item 1A. RISK FACTORS.**

Not required for emerging growth companies.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On March 21, 2023, we issued 1,500,000 shares of our common stock at a price of $0.10 per share to an accredited investor resulting in net proceeds to the Company of $150,000. We incurred no cost related to the private transaction. The net proceeds were used for the debt reduction. The issuance of the shares was exempt from registration under the Securities Act of 1933 in reliance on an exemption provided by Section 4(a)2 of that act.

**Item 3. DEFAULTS UPON SENIOR SECURITIES.**

On various dates during the month of March 2018 we issued a series of 5% Convertible Promissory Notes (collectively, the "5% Notes") totaling $750,000 in face amount. The 5% Notes bear interest at the rate of five percent (5%) per annum, compounded annually, and initially matured one-year from the date of issuance. As of March 15, 2023, 5% Notes with face amounts totaling $575,000 have been converted into common stock of the Company. 5% Notes with face amounts totaling $175,000 have matured and are currently in default for non-payment of principal and related accrued interest of $48,434 as of the filing date of this interim report.

**Item 4. MINE SAFETY DISCLOSURES**

Not applicable.

**Item 5. OTHER INFORMATION**

None.

**Item 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 31.1 | [Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*](ex31-1.htm) |
| 31.2 | [Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*](ex31-2.htm) |
| 32.1 | [Chief Executive Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*](ex32-1.htm) |
| 32.2 | [Chief Financial Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*](ex32-2.htm) |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Healthcare Integrated Technologies, Inc. | Healthcare Integrated Technologies, Inc. |
| Date: March 22, 2023 |  |  |
|  | By: | */s/ Scott M. Boruff* |
|  |  | Scott M. Boruff |
|  |  | President, Chief Executive Officer |
|  |  | (Principal Executive Officer) |
|  | Healthcare Integrated Technologies, Inc. | Healthcare Integrated Technologies, Inc. |
| Date: March 22, 2023 |  |  |
|  | By: | */s/ Charles B. Lobetti, III* |
|  |  | Charles B. Lobetti, III |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Scott M. Boruff, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly
 Report on Form 10-Q (this "Report") of Healthcare Integrated Technologies, Inc. (the "Registrant");

2. Based on my knowledge,
 this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
 made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
 Report;

3. Based on my knowledge,
 the financial statements, and other financial information included in this Report, fairly present in all material respects the financial
 condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

4. The Registrant's
 other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
 Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f)
 and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure
 controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
 information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
 particularly during the period in which this Report is being prepared;

b) designed such internal
 control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
 external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness
 of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness
 of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation;

d) disclosed in this Report
 any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent
 fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
 reasonably likely to materially affect, the Registrant's internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;5. The Registrant's
 other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
 to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the
 equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies
 and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
 affect the Registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not
 material, that involves management or other employees who have a significant role in the Registrant's internal controls over
 financial reporting.

---

| | | |
|:---|:---|:---|
| Date: March 22, 2023 | By: | */s/ Scott M. Boruff* |
|  |  | Scott M. Boruff |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Charles B. Lobetti, III, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly
 Report on Form 10-Q (this "Report") of Healthcare Integrated Technologies, Inc. (the "Registrant");

2. Based on my knowledge,
 this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
 made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
 Report;

3. Based on my knowledge,
 the financial statements, and other financial information included in this Report, fairly present in all material respects the financial
 condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

4. The Registrant's
 other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
 Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f)
 and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) designed such disclosure
 controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
 information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
 particularly during the period in which this Report is being prepared;

b) designed such internal
 control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
 external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness
 of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness
 of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation;

d) disclosed in this Report
 any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent
 fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
 reasonably likely to materially affect, the Registrant's internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;5. The Registrant's
 other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
 to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the
 equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies
 and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
 affect the Registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not
 material, that involves management or other employees who have a significant role in the Registrant's internal controls over
 financial reporting.

---

| | | |
|:---|:---|:---|
| Date: March 22, 2023 | By: | */s/ Charles B. Lobetti, III* |
|  |  | Charles B. Lobetti, III |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE**

**SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Healthcare Integrated Technologies, Inc. (the "Company"), on Form 10-Q for the period ended January 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Scott M. Boruff, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies
 with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained
 in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: March 22, 2023 | By: | */s/ Scott M. Boruff* |
|  |  | Scott M. Boruff |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE**

**SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Healthcare Integrated Technologies, Inc. (the "Company"), on Form 10-Q for the period ended January 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles B. Lobetti, III, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies
 with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained
 in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: March 22, 2023 | By: | */s/ Charles B. Lobetti, III* |
|  |  | Charles B. Lobetti, III |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---